This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulations 42ZCZS and 42ZCZX, this notice publishes:
- Decisions made by a delegate of the Secretary pursuant to regulations 42ZCZR, 42ZCZW and 42ZCZU.
- reasons for that final decision
- date of effect of the decision.
Final decisions in relation to dihydrocodeine and ethyl lactyl retinoate
Final decisions on dihydrocodeine and ethyl lactyl retinoate have been deferred while the submissions received from the consultation on interim decisions on these two substances are further considered.
Final decisions and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
Notice of final decisions to amend (or not amend) the current Poisons Standard
- Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #44, March 2024)
- Cytisine
- Dextromethorphan
Ethylmorphine
- Final decisions on proposed amendments referred to the Advisory Committee on Chemicals Scheduling (ACCS #38, March 2024)
- Niclosamide
- Niclosamide
- Final decisions on proposed amendments referred to the Advisory Committees on Medicines and Chemicals Scheduling in joint session (ACMS-ACCS #36, March 2024)
- Oxytetracycline
- tranexamic acid
- Delegate-only decisions
- Dimethylacetamide
- Epyrifenacil
- Metarylpicoxamid
- Moxidectin
- Vatinoxan hydrochloride
- Homobrassinolide
- Azelaic acid
- Prescription only (Schedule 4) substances contained within research-only kits in very small amounts
- Amendments to the Poison Standard initiated by the Delegate
- Thiafentanil
- Phenidines
- Carbendazim
- Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- Vutrisiran
- Ritlecitinib
- Odevixibat
- Pinaverium bromide
- Lumasiran
- Capivasertib
- Vorasidenib
- Fruquintinib
- Iptacopan
- Danicopan
- Sotatercept